We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed at $117.10 in the latest trading session, marking a -1.65% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.24% for the day. On the other hand, the Dow registered a loss of 0.01%, and the technology-centric Nasdaq decreased by 0.26%.
The pharmaceutical company's shares have seen an increase of 4.28% over the last month, surpassing the Medical sector's loss of 0.68% and falling behind the S&P 500's gain of 6.42%.
The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. The company is scheduled to release its earnings on April 30, 2026. The company's earnings per share (EPS) are projected to be -$1.01, reflecting a 145.5% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.99 billion, up 2.97% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.93 per share and revenue of $66.69 billion, indicating changes of -45.1% and +2.58%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.33% lower. Right now, Merck possesses a Zacks Rank of #3 (Hold).
Investors should also note Merck's current valuation metrics, including its Forward P/E ratio of 24.17. Its industry sports an average Forward P/E of 14.53, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 2.39. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.36 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 173, finds itself in the bottom 30% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK - Free Report) closed at $117.10 in the latest trading session, marking a -1.65% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.24% for the day. On the other hand, the Dow registered a loss of 0.01%, and the technology-centric Nasdaq decreased by 0.26%.
The pharmaceutical company's shares have seen an increase of 4.28% over the last month, surpassing the Medical sector's loss of 0.68% and falling behind the S&P 500's gain of 6.42%.
The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. The company is scheduled to release its earnings on April 30, 2026. The company's earnings per share (EPS) are projected to be -$1.01, reflecting a 145.5% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.99 billion, up 2.97% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.93 per share and revenue of $66.69 billion, indicating changes of -45.1% and +2.58%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.33% lower. Right now, Merck possesses a Zacks Rank of #3 (Hold).
Investors should also note Merck's current valuation metrics, including its Forward P/E ratio of 24.17. Its industry sports an average Forward P/E of 14.53, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 2.39. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.36 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 173, finds itself in the bottom 30% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.